New drug cocktail aims to beat tough lymphoma

NCT ID NCT07001384

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of two drugs, alectinib and duvelisib, in 30 people with a rare type of blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe dose and see if the combination can lead to lasting remission after treatment ends.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alectinib and duvelisib
What this could lead to: If successful, this could provide a new, time-limited treatment option for people with relapsed or refractory ALK+ ALCL, potentially leading to long-term remission without continuous therapy.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The combination may cause significant side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-positive anaplastic large cell lymphoma anaplastic large cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LARGE CELL LYMPHOMA ANAPLASTIC LYMPHOMA KINASE

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.